Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

AMGN, NVS launch Humira biosimilars in Europe, pursuant

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 720
Posts 108,602
Boards Moderated 21
Alias Born 09/05/02
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 7/16/2019 4:44:01 PM
Form 8.3 - [Allergan plc] Dow Jones News - 7/16/2019 10:44:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 7/15/2019 10:55:00 AM
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma PR Newswire (US) - 7/15/2019 8:00:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 7/12/2019 10:53:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 7/11/2019 10:40:00 AM
AbbVie to Host Second-Quarter 2019 Earnings Conference Call PR Newswire (US) - 7/11/2019 8:00:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 7/10/2019 11:09:00 AM
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue PR Newswire (US) - 7/10/2019 6:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/9/2019 5:01:57 PM
CytomX Therapeutics Up 9%; AbbVie Picks Second Target Under Collaboration Dow Jones News - 7/9/2019 11:55:00 AM
Form 8.3 - Allergan Plc] Dow Jones News - 7/9/2019 10:48:00 AM
Trump Rule Requiring Drug Prices in TV Ads Blocked -- Update Dow Jones News - 7/8/2019 10:25:00 PM
Form 8.3 - [Allergan plc] Dow Jones News - 7/8/2019 10:44:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 7/4/2019 10:44:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 7/3/2019 11:02:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2019 1:14:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2019 1:14:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2019 1:13:54 PM
Form 8.3 - [Allergan plc] Dow Jones News - 7/2/2019 10:30:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 7/1/2019 11:20:00 AM
U.S. Leads in Deals as World Lags -- WSJ Dow Jones News - 7/1/2019 3:02:00 AM
U.S. Deals Lead the Way as Rest of the World Lags Behind Dow Jones News - 6/30/2019 11:29:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 4:49:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 4:49:05 PM
DewDiligence Member Level  Tuesday, 10/16/18 11:23:52 AM
Re: None
Post # of 468 
AMGN, NVS launch Humira biosimilars in Europe, pursuant to prior settlements with ABBV (#msg-134970085, #msg-144157243):

https://uk.reuters.com/article/us-abbvie-biosimilars/amgen-novartis-kick-off-fight-for-abbvie-blockbuster-drug-in-eu-idUKKCN1MQ1QT

Two additional Humira biosimilars—from MYL and Samsung—are expected to launch in Europe soon.

No pricing information on Humira biosimilars in Europe has been publicly disclosed yet.

The formulation and method-of-use patents that ABBV has used to keep Humira biosimilars off the market in the US until 2023 did not stand up to challenge in Europe.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist